A study released on October 26, 2006 by The New England Journal of Medicine regarding lung cancer detections further validates a significant class action tobacco lawsuit filed by New York City product liability lawyers, Levy Phillips & Konigsberg. The October 26th New England Journal of Medicine reports the results of a study demonstrating that annual low-dose CT screening offers early lung cancer detections (Stage 1) in 85% of the cases in which lung cancer is detected by this break-through technology. The 10-year survival rate in patients raises by 92% when lung cancer is detected early and promptly surgically removed.
The class action tobacco lawsuit asks Phillip Morris to accept tobacco corporate responsibility and provide annual low-dose CT Screening for a class of residents in New York State who are 50 years of age or older and have smoked a pack a day of Marlboro cigarettes for at least 20 years. These early lung cancer detections could significantly decreasing the number of deaths from lung cancer -- the No. 1 cause of cancer deaths.
“Lung cancer is the leading cause of cancer death in the United States and the State of New York. Over 160,000 people die annually in the U.S. from this awful disease,” said Jerome Block of Levy Phillips & Konigsberg. “Lung cancer deaths can be prevented since lung cancer is usually curable when diagnosed in its early stage. Philip Morris seeks to blame addicted smokers for what it calls ‘personal responsibility’. We are asking Phillip Morris to accept ‘tobacco corporate responsibility’ and save their customers’ lives by provide low-dose CT Screening of the chest for early detection of lung cancer,” says Mr. Block, one of the leading New York City product liability lawyers.
